Stock Pulse
Stryker (SYK) completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, forming a strategic partnership with the new VB Spine [7], [8]. While this divestiture narrows their direct spine market involvement, it allows for focused resource allocation to higher-growth areas [7], [8]. The company anticipates releasing Q1 2025 results on May 1st [6]. Despite positive factors like strong organic growth, a robust free cash flow margin, and recent product launches and acquisitions [1], [4], concerns exist regarding high valuation and potential negative impacts from trade tensions and tariffs [1], [2], [3], [9]. A "sell" rating from Zacks based on comparative valuation metrics against Prestige Consumer Healthcare adds to these concerns [2]. Positive indicators include an upgraded Relative Strength Rating [5] and insider stock acquisitions [10], [11], [12], though these are less impactful than the strategic and market factors.